Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

That differs by molecule, by company, by stage ... For example, Merck [& Co.] has over 480 combination products with Keytruda ...

Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year?

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

They include: Pipeline and key clinical candidates for these companies: Rapt Therapeutics is focused on discovering, developing and commercializing oral small molecule therapies for patients with ...

Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -- Phase 1 ...

The structure of a small molecule can also be shown as a three-dimensional ball-and-stick model. These models show how the atoms and bonds are arranged in space. The diagram shows a ball-and-stick ...